Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.

Margaret S Sozio,Naga Chalasani

doi:10.1002/hep.27363

Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.

Margaret S Sozio, Naga Chalasani

Open Access

PDF Available

https://doi.org/10.1002/hep.27363

Copy DOI

Export

Save

Cite

Journal: Hepatology	Publication Date: Oct 2, 2014
Citations: 12

Affiliation: Richard L. Roudebush VA Medical Center

#Active Bleeding #Composite Endpoint #Acute Bleeding #Variceal Bleeding #Primary Endpoint #Active Variceal Bleeding #Bleeding In Cirrhosis #Risk Of Arterial Thromboembolic Events #Failure Rate #High Risk For Thrombotic Events

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Hepatology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.